As expected, the International Society for Stem Cell Research (ISSCR) has updated its guidelines for stem cell research. The marquee guideline is the relaxation of the limit of 14 days on how long a human embryo may be kept alive in a lab. According to the ISSCR the update reflects emerging advances including stem cell-based embryo models, human embryo research, chimeras, organoids, genome editing and ectogenesis.
Deafness is the most common sensory impairment in newborn children about 1 child in 1000 is born with hearing loss, or develops it in early childhood.Half of these cases have a genetic cause; very often, this type of deafness is related to a mutation of a gene called 'gap junction beta 2 (GJB2)', which encodes a protein called 'connexin 26 (CX26)'. This protein occurs in cells in the cochlea, the part of the inner ear enabling hearing. One way of treating GJB2-related deafness would be to reproduce properly functioning cochlear cells and introduce them into the inner ear
Limit on lab-grown human embryos dropped by stem-cell body Nature.com Human Stem Cell Research Guidelines Updated The Scientist Stem cell guidelines open door to more permissive research on human embryos Science Magazine New global guidelines for stem cell research aim to drive discussions, not lay down the law The Conversation AU Citing stem cell advances, ISSCR extends permissible limit on human embryo research BioWorld Online View Full Coverage on Google News
TOPEKA Lt.
Magenta Therapeutics is losing its chief medical officer and head of R&D John Davis, M.D., with his last day coming July 30. Davis helped steer the biotechs early path as well as deals with Avrobio and base editing biotech Beam Therapeutics around its lead stem cell conditioning program, MGTA-117, and MGTA-145 as a potentially new first-line standard of care for stem cell mobilization in a broad range of diseases
Synthetic Stem Cells Market report delivers a far-reaching market research on the current conditions of the industry, potential of the market in the present and the future prospects from various points of views. Market drivers and market restraints evaluated in this report gives clear understanding about how the product is getting utilized in the recent period and also offer estimations about the future usage
Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new research being highlighted as part of the Companys fourth annual Science Day. Modernas Science Day is designed to provide insight into the continued diverse efforts underway at Moderna to better understand how to use mRNA as medicines and vaccines and underscores the Companys continued commitment to basic science and innovation. Science Day gives us an opportunity to provide insights into the advancements in our platform science and our further understanding of how to use mRNA as both a vaccine and a medicine
New York, May 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell and Gene Therapy CROs Market by Type of Therapy, Scale of Operation, Preclinical Services Offered, Clinical Services Offered, and Geography : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06076407/?utm_source=GNW Presently, over 30 cell and gene therapies have received marketing approval, while around 1,000 therapeutic leads are under evaluation. Considering the advantages of ATMPs, and their ability to address the underlying causes of several serious clinical conditions wherein small molecule drugs have been proven to be inadequate, the preference for such therapeutic modalities is on the rise. In fact, experts believe that, by 2030, 40 - 60 such products are likely to be approved in the US alone
In response to the technological advances of recent years, the International Society for Stem Cell Research today (May 26) released an updated version of its guidelines for basic and clinical research involving human stem cells and embryos. The ISSCRs changes include recommendations for using human embryo models, lab-derived gametes, and human-animal chimeras as well as an end to the widely accepted two-week maximum for growing human embryos in culture
Recent Comments